MFT Inhibitors
MFT inhibitors primarily revolve around compounds that target the folate metabolism pathway. Since MFT is a key player in the transport of folates into mitochondria, affecting the availability or metabolism of these folates can indirectly affect MFT's function. Methotrexate, Pemetrexed, and Pyrimethamine, for instance, hinder enzymes vital to folate metabolism, like dihydrofolate reductase. With the disruption of these enzymes, the intracellular folate pool can diminish, leading to reduced substrate availability for MFT transport.
On the other hand, compounds like Raltitrexed and 5-Fluorouracil specifically target thymidylate synthase, an enzyme critical in the folate pathway. Any disturbance to this enzyme can indirectly affect MFT's transport role. Other compounds, such as 6-Mercaptopurine and Thymidine, introduce an indirect effect. By altering related pathways, such as purine metabolism, they can influence the folate pathway and, by extension, MFT's function. Lastly, agents like Folinic acid (Leucovorin) can introduce a potential feedback mechanism. Excessive amounts of active folates might saturate the system, indirectly inhibiting MFT's role.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $92.00 $209.00 | 33 | |
An antifolate that inhibits dihydrofolate reductase, leading to decreased folate availability and potential reduction in MFT transport. | ||||||
Pemetrexed Disodium | 150399-23-8 | sc-219564 | 10 mg | $133.00 | 5 | |
Interferes with enzymes involved in folate metabolism. Reduced intracellular folate can decrease the substrate available for MFT. | ||||||
Raltitrexed | 112887-68-0 | sc-219933 | 10 mg | $143.00 | ||
Targets thymidylate synthase, a key enzyme in the folate pathway, indirectly affecting MFT's transport function. | ||||||
Pyrimethamine | 58-14-0 | sc-208190 sc-208190A sc-208190B | 1 g 5 g 25 g | $78.00 $233.00 $809.00 | 5 | |
Inhibits dihydrofolate reductase, thus affecting the folate pool and potentially MFT's transport function. | ||||||
Trimethoprim | 738-70-5 | sc-203302 sc-203302A sc-203302B sc-203302C sc-203302D | 5 g 25 g 250 g 1 kg 5 kg | $66.00 $158.00 $204.00 $707.00 $3334.00 | 4 | |
Another inhibitor of dihydrofolate reductase, reducing the folate pool available for MFT transport. | ||||||
Sulfasalazine | 599-79-1 | sc-204312 sc-204312A sc-204312B sc-204312C | 1 g 2.5 g 5 g 10 g | $60.00 $75.00 $125.00 $205.00 | 8 | |
Inhibits dihydropteroate synthetase, potentially reducing folate intermediates available for MFT transport. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $36.00 $149.00 | 11 | |
Targets thymidylate synthase, potentially affecting the availability of folate intermediates for MFT. | ||||||
6-Mercaptopurine | 50-44-2 | sc-361087 sc-361087A | 50 mg 100 mg | $71.00 $102.00 | ||
Alters purine metabolism, which can indirectly influence the folate pathway and MFT's function. | ||||||
Thymidine | 50-89-5 | sc-296542 sc-296542A sc-296542C sc-296542D sc-296542E sc-296542B | 1 g 5 g 100 g 250 g 1 kg 25 g | $48.00 $72.00 $265.00 $449.00 $1724.00 $112.00 | 16 | |
Can lead to an imbalance in nucleotide pools, potentially affecting the folate metabolism pathway and indirectly influencing MFT's role. | ||||||
3′-Azido-3′-deoxythymidine | 30516-87-1 | sc-203319 | 10 mg | $60.00 | 2 | |
Another nucleoside analogue that may indirectly impact folate metabolism and subsequently MFT's function. | ||||||